ABL1 anticorps

N° du produit ABIN498860

Détail du produit anti-ABL1 anticorps

Antigène: ABL1 (C-Abl Oncogene 1, Non-Receptor tyrosine Kinase (ABL1))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp ABL1 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Specificité: This antibody detects endogenous levels of Abl1 protein.

Réactivité croisée (Details): Species reactivity (expected):Mouse and Rat.
Species reactivity (tested):Human.

Purification: Affinity chromatography using epitope-specific immunogen

Pureté: > 95 % (by SDS-PAGE)

Information d'application

Indications d'application: Western blot: 1: 500 - 1: 1000. Immunohistochemistry on paraffin sections: 1: 50 - 1: 200.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 1.0 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.2, 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store at 2 - 8 °C for up to one month or (in aliquots) at -20 °C for longer.

Détails sur ABL1

Antigène: ABL1 (C-Abl Oncogene 1, Non-Receptor tyrosine Kinase (ABL1))

Autre désignation: ABL1 (ABL1 Produits)

Synonymes: anticorps ABL, anticorps JTK7, anticorps bcr/abl, anticorps c-ABL, anticorps p150, anticorps v-abl, anticorps AI325092, anticorps Abl, anticorps E430008G22Rik, anticorps c-Abl, anticorps ABL proto-oncogene 1, non-receptor tyrosine kinase, anticorps c-abl oncogene 1, non-receptor tyrosine kinase, anticorps Tyrosine-protein kinase abl-1, anticorps ABL1, anticorps Abl1, anticorps abl-1, anticorps abl1

Sujet: The c Abl proto oncogene encodes a protein tyrosine kinase that is located in the cytoplasm and nucleus. In chronic myelogenous leukemia and in a subset of acute lymphoblastic leukemias, the c Abl proto oncogene undergoes a (9,22) chromosomal translocation producing a novel rearranged chromosome (the Philadelphia chromosome) As the result of the fusion of c Abl sequences from chromosome 9 to the Bcr gene on chromosome 22. The molecular consequence of this translocation is the generation of a chimeric Bcr/Abl mRNA encoding activated Abl protein tyrosine kinase.Protein tyrosine kinases play important roles in the transduction of extracellular signals. Receptor tyrosine kinases include a myriad of growth factor receptors, which are activated upon ligand binding. Differential binding of adapter proteins may impart some signal specificity, since many of the receptors use the same adapter proteins, and may also link the activation of the receptor to multiple pathways. In contrast, nonreceptor tyrosine kinases are recruited to substrates and or activators by their SH2 and/or SH3 domains. These domains also allow them to interact with activated receptor tyrosine kinases. These kinases are divided into several groups, including the Src, Jak, Abl, Fak, Fps, Csk, Syk and Btk families, and are components of intracellular signaling cascades.Synonyms: Abelson murine leukemia viral oncogene homolog 1, JTK7, Proto-oncogene tyrosine-protein kinase ABL1, bcr/abl, c-ABL, p150

Poids moléculaire: approx. 123 kDa

ID gène: 25

NCBI Accession: NP_005148

UniProt: P00519

Pathways: Apoptose, Regulation of Muscle Cell Differentiation, Platelet-derived growth Factor Receptor Signaling, Lipid Metabolism